14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:XLRN
Delisted

Acceleron Pharma Inc. Stock Price (Quote)

$178.75
+0 (+0%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $178.75 $178.75 Friday, 27th May 2022 XLRN stock ended at $178.75. During the day the stock fluctuated 0% from a day low at $178.75 to a day high of $178.75.
90 days $178.75 $178.75
52 weeks $113.49 $189.99

Historical Acceleron Pharma Inc. prices

Date Open High Low Close Volume
Oct 22, 2021 $174.23 $174.42 $173.50 $173.95 196 871
Oct 21, 2021 $174.00 $174.35 $173.10 $173.75 633 929
Oct 20, 2021 $173.77 $174.25 $172.25 $172.51 499 975
Oct 19, 2021 $173.04 $174.30 $173.04 $173.74 363 155
Oct 18, 2021 $173.25 $174.40 $172.85 $173.00 611 183
Oct 15, 2021 $172.93 $173.55 $171.91 $172.94 408 525
Oct 14, 2021 $173.75 $174.86 $172.02 $172.08 1 123 567
Oct 13, 2021 $173.75 $174.30 $172.23 $172.59 1 074 534
Oct 12, 2021 $175.34 $179.49 $173.28 $173.78 2 481 438
Oct 11, 2021 $175.10 $175.89 $174.49 $174.99 861 536
Oct 08, 2021 $175.80 $176.19 $174.81 $175.00 1 270 145
Oct 07, 2021 $175.87 $176.50 $175.03 $175.33 2 167 870
Oct 06, 2021 $176.62 $176.97 $175.27 $175.29 1 100 895
Oct 05, 2021 $174.99 $177.20 $174.24 $177.13 2 124 818
Oct 04, 2021 $173.63 $175.23 $173.21 $174.68 1 573 571
Oct 01, 2021 $172.50 $175.07 $172.27 $174.35 2 789 958
Sep 30, 2021 $175.09 $175.60 $171.75 $172.10 14 686 979
Sep 29, 2021 $183.00 $189.99 $175.25 $175.36 4 039 499
Sep 28, 2021 $179.49 $187.70 $178.60 $182.78 2 107 844
Sep 27, 2021 $173.00 $182.44 $173.00 $178.87 1 889 566
Sep 24, 2021 $158.94 $174.24 $158.52 $167.65 1 231 013
Sep 23, 2021 $154.69 $161.35 $154.57 $159.84 767 907
Sep 22, 2021 $153.36 $154.72 $149.33 $154.44 371 514
Sep 21, 2021 $140.46 $153.86 $139.76 $153.29 1 017 814
Sep 20, 2021 $135.94 $140.06 $134.99 $139.55 440 613
Click to get the best stock tips daily for free!

About Acceleron Pharma Inc.

Acceleron Pharma. Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of protein therapeutics for cancer and rare diseases. It is developing sotatercept to treat patients with chronic kidney disease, including mineral-bone disorder, vascular calcification, and anemia; and luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassem... XLRN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT